Skip to main content
SpringerLink
Log in

Valutazione economica della terapia con lisinopril ad alto verso basso dosaggio nel trattamento dei soggetti con scompenso cardiaco cronico

Economic evaluation of high vs low dosage lisinopril in patients with chronic heart failure

  • Published:
PharmacoEconomics Italian Research Articles

Summary

Objective

To compare the economic consequences of treating chronic heart failure (CHF) with high versus low dosage lisinopril.

Design

A cost-effectiveness analysis compared cost and effects of lisinopril 32.5–35 versus 2.5–5 mg/die in the perspective of the Italian National Health Service (NHS). Effects and resources absorption were derived from the ATLAS results. Pharmacological costs were quantified according to the Italian market price of the drug; hospitalisation costs were quantified on the basis of DRG tariffs. Effects are expressed as reduction of cardiovascular morbidity and mortality and life-years saved (LYS). For both costs and effects a 5% annual discount was applied.

Setting

CHF patients in an hypothetical Italian setting, according to the ATLAS design.

Patients and participants

More than 3000 patients with NYHA classes II to IV, CHF and left ventricular ejection fractions equal or less than 0.30.

Main outcome measures and results

Clinical effects of treating 1000 patients for 3.58 years with high versus low dosage lisinopril would correspond to a saving of € 99.300. The therapy with high dosage of lisinopril dominates the alternative with the low dosage of the drug.

Conclusions

Treating CHF patients with high dosage of lisinopril is not only more effective but also less costly than with low dosage of the drug. The incremental pharmacological costs are offset by savings in hospitalisations costs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Bibliografia

  1. Cowie MR, Wood DA, Coats AJS, et al. Incidence and aetiology of heart failure. A population-based study. Eur Heart J 1999; 20: 421–8

    Article  CAS  PubMed  Google Scholar 

  2. The SEOSI Investigators. Survey on heart failure in Italian hospital cardiology units. Results of the SEOSI study. Eur Heart J 1997; 18: 1457–64

    Article  Google Scholar 

  3. Misuraca G, Serafini O, Caporale R, et al. Prevalenza e caratteristiche cliniche dell’insufficienza cardiaca in un campione di popolazione della Calabria. G Ital Cardiol 1998; 28: 1385–90

    CAS  PubMed  Google Scholar 

  4. Stafford RS, Saglam D, Blumenthal D. National patterns of Angiotensin-converting enzyme inhibitor use in congestive heart failure. Arch Intern Med 1997; 157: 2460–4

    Article  CAS  PubMed  Google Scholar 

  5. McMurray JJ, Steward S. Heart Failure. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000; 83: 596–602

    Article  CAS  PubMed  Google Scholar 

  6. Albanese MC, Plewka M, Gregori D, et al. Use of medical resources and quality of life of patients with chronic heart failure: a prospective survey in a large Italian community hospital. Eur J Heart Fail 1999; 1: 411–7

    Article  CAS  PubMed  Google Scholar 

  7. Sinagra GF, Perkan A, Zecchin M, et al. L’epidemiologia dello scompenso cardiaco: un problema crescente di sanità pubblica. G Ital Cardiol 1995; 25: 1043–53

    CAS  PubMed  Google Scholar 

  8. Senni M, Gavazzi A. How patients with heart failure are managed in Italy. Eur J Heart Fail 2001; 3: 257–60

    Article  CAS  PubMed  Google Scholar 

  9. Berry C, Murdoch DR, McMurray JJV. Review article. Economics of chronic heart failure. Eur J Heart Fail 2000; 2: 283–91

    Google Scholar 

  10. Ambrosio GB, Riva LM, Zamboni S, et al. Lo scompenso di cuore nella popolazione: dati di prevalenza. Cardiologia 1992; 37: 235–9

    Google Scholar 

  11. Linné AB, Liedholm H, Jendteg S, Israelsson B. Health care costs of heart failure: results from a randomised study of patient education. Eur Heart J 2000; 2: 291–7

    Article  Google Scholar 

  12. Cleland JGF. Health economic consequences of the pharmacological treatment of heart failure. Eur Heart J 1998; 19 (suppl P): P3–P39

    Google Scholar 

  13. Picenni A, Cocci A, Monina G, et al. Epidemiologia della cronicità cardiovascolare. Una proposta metodologica generale della SIFO-Lombardia. Giornale Italiano di Farmacia Clinica 2000; 4(1): 16–20

    Google Scholar 

  14. Bellotti P, Padano LP, Acquarone N, et al. Specialty-related differences in the epidemiology, clinical profile, management and outcome of patients hospitalized for heart failure. The OSCUR Study. Eur Heart J 2001; 22: 596–604

    Article  CAS  PubMed  Google Scholar 

  15. Working Group: Heart Failure. Italian network on outpatients with heart failure (IN-CHF). ANMCO — Italian Association of Hospital Cardiologists. Research activities year 2000

  16. Simpson K, Blair J. Lisinopril. A review of its use in congestive heart failure. Drugs 2000; 59(5): 1149–67

    Article  CAS  PubMed  Google Scholar 

  17. Massie BM, Armstrong PW, Cleland JGF, et al. Toleration of high doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure. Results from the ATLAS Study. Arch Intern Med 2001; 161: 165–71

    Article  CAS  PubMed  Google Scholar 

  18. Andersson F, Cline C, Rydén-Bergsten T, et al. Angiotensin converting enzyme (ACE) inhibitors and heart failure: the consequences of underprescribing. Pharmacoeconomics 1999; 15(6): 535–50

    Article  CAS  PubMed  Google Scholar 

  19. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312–18

    Article  CAS  PubMed  Google Scholar 

  20. Lancaster SG, Todd PA. Lisinopril: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1988; 35: 646–69

    Article  CAS  PubMed  Google Scholar 

  21. Langtry HD, Markham A. Lisinopril: a review of its pharmacology and clinical efficacy in elderly patients. Drugs Aging 1997; 10: 131–66

    Article  CAS  PubMed  Google Scholar 

  22. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity; the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751–6

    Article  CAS  PubMed  Google Scholar 

  23. Goa KL, Haria M, Wilde MI. Lisinopril: a review of its pharmacology and use in the management of complications of diabetes mellitus. Drugs 1997; 53: 1081–105

    Article  CAS  PubMed  Google Scholar 

  24. Goa KL, Balfour JA, Zuanetti G. Lisinopril: a review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction. Drugs 1996; 52: 564–88

    Article  CAS  PubMed  Google Scholar 

  25. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardio (GISSI-3). Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after myocardial infarction. Lancet 1994; 343: 1115–22

    Google Scholar 

  26. Agardh CD, Garcia-Puig J, Charbonnel S, et al. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996; 10: 185–92

    CAS  PubMed  Google Scholar 

  27. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787–92

    Article  Google Scholar 

  28. Chatuvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28–31

    Article  Google Scholar 

  29. Franzosi MG, Maggioni AP, Santoro E, et al. Cost-effectiveness analysis of early lisinopril use in patients with acute myocardial infarction: Results from GISSI-3 trial. Pharmacoeconomics 1998; 13: 337–46.

    Article  CAS  PubMed  Google Scholar 

  30. Packer M. Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? J Am Coll Cardiol 1996; 333: 1670–6

    Google Scholar 

  31. Uretsky BF, Shaver JA, Liang CS, et al. Modulation of hemodynamic effects with converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observation on long-term clinical, functional and biochemical responses. Am Heart J 1988; 116: 480–8

    Article  CAS  PubMed  Google Scholar 

  32. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987; 316: 1429–35

    Article  Google Scholar 

  33. The SOLVD Investigators. Effect of Enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 292–302

    Article  Google Scholar 

  34. Katz DA, Welch HG. Discounting in cost-effectiveness analysis of Healthcare Programmes. Pharmacoeconomics 1993; 3(4): 276–85

    Article  CAS  PubMed  Google Scholar 

  35. Sculpher MJ, Poole L, Cleland JGF, et al. Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the assessment of treatment with lisinopril and survival (ATLAS) study. Eur J Heart Fail 2000; 2: 447–454

    Article  CAS  PubMed  Google Scholar 

  36. Informatore Farmaceutico. Italian Directory of Medicines and Manufacturers, n∘ 60. Milano: OEMF, 2001

    Google Scholar 

  37. Mason J, Young P, Freemantle N, Hobbs R. Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: analysis of individual patient data from studies of left ventricular dysfunction. BMJ 2000; 321: 1113–6

    Article  CAS  PubMed  Google Scholar 

  38. Decreto Ministeriale 22/07/96. “Prestazioni di assistenza specialistica ambulatoriale erogabili nell’ambito del Servizio sanitario nazionale e relative tariffe”. Supplemento ordinario alla Gazzetta Ufficiale n. 216, 14/09/1996

  39. Decreto Ministeriale 14/12/1994. “Tariffe delle prestazioni di assistenza ospedaliera”. Supplemento ordinario alla Gazzetta Ufficiale n. 209, 08/09/1997

  40. Cleland JGF. Causes of death in the ATLAS study: effects of high-dose ACE-inhibitors. Intern J Clin Pract 1999; suppl 100: 19–20

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centro di Farmacoeconomia, Dipartimento di Scienze Farmacologiche, Università degli Studi di Milano, Via Balzaretti 9, 20133, Milano, Italia

    L. Scalone &  Lorenzo G. Mantovani

Authors
  1. L. Scalone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lorenzo G. Mantovani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lorenzo G. Mantovani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scalone, L., Mantovani, L.G. Valutazione economica della terapia con lisinopril ad alto verso basso dosaggio nel trattamento dei soggetti con scompenso cardiaco cronico. Pharmacoeconomics-Ital-Res-Articles 4, 45–55 (2002). https://doi.org/10.1007/BF03320594

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03320594

Search

Navigation